The role for interleukin-12 therapy of cutaneous T cell lymphoma

Alain H. Rook; Mohamed H. Zaki; Maria Wysocka; Gary S. Wood; Madeleine Duvic; Louise C. Showe; Francine Foss; Michael Shapiro; Timothy M. Kuzel; Elise A. Olsen; Eric C. Vonderheid; Robert Laliberte; Matthew L. Sherman

doi:10.1111/j.1749-6632.2001.tb03721.x

The role for interleukin-12 therapy of cutaneous T cell lymphoma

Alain H. Rook
, Mohamed H. Zaki
, Maria Wysocka
, Gary S. Wood
, Madeleine Duvic
, Louise C. Showe
, Francine Foss
, Michael Shapiro
, Timothy M. Kuzel
, Elise A. Olsen
, Eric C. Vonderheid
, Robert Laliberte
, Matthew L. Sherman

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8⁺ and/or TIA-1⁺ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

Original language	English (US)
Pages (from-to)	177-184
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	941
DOIs	https://doi.org/10.1111/j.1749-6632.2001.tb03721.x
State	Published - 2001
Externally published	Yes

Keywords

Interferon-γ
Interleukin-2
Recombinant human interleukin-12

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2001.tb03721.x

Cite this

@article{f47eb29a5fe34aed82a9829fd305ab11,

title = "The role for interleukin-12 therapy of cutaneous T cell lymphoma",

abstract = "Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.",

keywords = "Interferon-γ, Interleukin-2, Recombinant human interleukin-12",

author = "Rook, \{Alain H.\} and Zaki, \{Mohamed H.\} and Maria Wysocka and Wood, \{Gary S.\} and Madeleine Duvic and Showe, \{Louise C.\} and Francine Foss and Michael Shapiro and Kuzel, \{Timothy M.\} and Olsen, \{Elise A.\} and Vonderheid, \{Eric C.\} and Robert Laliberte and Sherman, \{Matthew L.\}",

year = "2001",

doi = "10.1111/j.1749-6632.2001.tb03721.x",

language = "English (US)",

volume = "941",

pages = "177--184",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - The role for interleukin-12 therapy of cutaneous T cell lymphoma

AU - Rook, Alain H.

AU - Zaki, Mohamed H.

AU - Wysocka, Maria

AU - Wood, Gary S.

AU - Duvic, Madeleine

AU - Showe, Louise C.

AU - Foss, Francine

AU - Shapiro, Michael

AU - Kuzel, Timothy M.

AU - Olsen, Elise A.

AU - Vonderheid, Eric C.

AU - Laliberte, Robert

AU - Sherman, Matthew L.

PY - 2001

Y1 - 2001

N2 - Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

AB - Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

KW - Interferon-γ

KW - Interleukin-2

KW - Recombinant human interleukin-12

UR - https://www.scopus.com/pages/publications/0034803597

UR - https://www.scopus.com/pages/publications/0034803597#tab=citedBy

U2 - 10.1111/j.1749-6632.2001.tb03721.x

DO - 10.1111/j.1749-6632.2001.tb03721.x

M3 - Article

C2 - 11594571

AN - SCOPUS:0034803597

SN - 0077-8923

VL - 941

SP - 177

EP - 184

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

The role for interleukin-12 therapy of cutaneous T cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this